Literature DB >> 27110284

The incidence and mortality of ovarian cancer and their relationship with the Human Development Index in Asia.

Saeid Razi1, Mahshid Ghoncheh2, Abdollah Mohammadian-Hafshejani3, Hojjat Aziznejhad4, Mahdi Mohammadian5, Hamid Salehiniya6.   

Abstract

BACKGROUND: The incidence and mortality estimates of ovarian cancer based on human development are essential for planning by policy makers. This study is aimed at investigating the standardised incidence rates (SIR) and standardised mortality rates (SMR) of ovarian cancer and their relationship with the Human Development Index (HDI) in Asian countries.
METHODS: This study was an ecologic study in Asia for assessment of the correlation between SIR, age standardised rates (ASR), and HDI and their details, including life expectancy at birth, mean years of schooling, and gross national income (GNI) per capita. We used the correlation bivariate method for assessment of the correlation between ASR and HDI, and its details. Statistical significance was assumed if P < 0.05. All reported P-values were two-sided. Statistical analyses were performed using SPSS (Version 15.0, SPSS Inc.).
RESULTS: The highest SIR of ovarian cancer was observed in Singapore, Kazakhstan, and Brunei respectively. Indonesia, Brunei, and Afghanistan had the highest SMR. There was a positive correlation between the HDI and SIR (r = 0.143, p = 0.006). Correlation between SMR of ovarian cancer and HDI was not significant (r = 0.005, p = 052.0).
CONCLUSION: According to the findings of this study, between the HDI and SIR, there was a positive correlation, but there was no correlation between the SMR and HDI.

Entities:  

Keywords:  Asia; Human Development Index; epidemiology; incidence; ovarian cancer

Year:  2016        PMID: 27110284      PMCID: PMC4817525          DOI: 10.3332/ecancer.2016.628

Source DB:  PubMed          Journal:  Ecancermedicalscience        ISSN: 1754-6605


Introduction

Ovarian cancer is the eighth most common cancer among women, and it includes about 4% of all women’s cancers [1]. This disease has high morbidity and mortality rates among cancers of the reproductive system [1, 2]. According to global estimates 225,000 new cases were detected each year, and 140,000 people annually die from the disease [1]. Lifetime risk of ovarian cancer in women is one in 71, and the chance of dying from the disease is 1 in 95 [3]. Although the incidence and mortality of this disease is high, its aetiology is not fully understood [4]. Nowadays, a few factors associated with this cancer have been identified [5]. These are classified into three categories: protective factors (parity and use of contraceptive), risk factors (lack of birth, a history of family, and age), and factors such as lactation, age at menarche, and age at menopause, while causality between them and the ovarian cancer is still not proven [5-8]. The incidence and mortality of this disease varies in different regions of the world. This may be because of a difference in genetic and environmental factors. In recent years, cancer as the cause of death was well-known in high-income countries, but in the coming years, regardless of socioeconomic status, it will be a major cause of disease and death. One of the important factors is the Human Development Index (HDI) [9-11], which shows the socioeconomic status of people living in different countries [12]. Since the HDI shows the status of the various countries in terms of progress and development, and because of the increasing burden of non-communicable diseases, especially in low-income countries [1, 13–15], the aim of this study was to investigate the relationship between HDI and incidence of and mortality from ovarian cancer in Asian countries.

Methods

This study was an ecologic study in Asia for assessment of the correlation between the age-specific incidence and mortality rate (ASR), and the HDI and its details, including life expectancy at birth, mean years of schooling, and gross national income (GNI) per capita. Data on the ASR for every Asian country for 2012 were obtained from the Global Cancer Project, which is available from (http://globocan.iarc.fr/Default.aspx), and data on the HDI was obtained from the Human Development Report 2013 [16], including specific information about the HDI and its details for every country in the word for 2012.

The method of estimation of the age-specific incidence and mortality rates in the Global Cancer Project by the International Agency for Research on Cancer (IARC)

Age-specific incidence rate estimate

The methods of estimation are specific for each country, and the quality of the estimation depends upon the quality and the amount of information available for each country. In theory, there are as many methods as there are countries, and because of the variety and the complexity of these methods, an overall quality score for the incidence and mortality estimates combined is almost impossible to establish. However, an alphanumeric scoring system that independently describes the availability of incidence and mortality data has been established at the country level. The combined score is presented together with the estimates for each country with the aim of providing a wide indication of the robustness of the estimation. The methods to estimate the sex- and age-specific incidence rates of cancer for a specific country fall into one of the following extensive categories, in priority order: 1. Rates projected to 2012 (38 countries); 2. Most recent rates applied to 2012 population (20 countries); 3. Estimated from national mortality by modeling, using incidence and mortality ratios derived from recorded data in country-specific cancer registries (13 countries); 4. Estimated from national mortality by modeling using incidence mortality ratios derived from recorded data in local cancer registries in neighbouring countries (nine European countries); 5. Estimated from national mortality estimates using modeled survival (32 countries); 6. Estimated as the weighted average of the local rates (16 countries); 7. One cancer registry covering a part of a country as a representative of the country profile (11 countries); 8. Age/sex specific rates for ‘all cancers’ partitioned using data on the relative frequency of different cancers (by age and sex) (12 countries); and 9. The rates are those of neighbouring countries or registries in the same area (33 countries) [17, 18].

Age-specific mortality rate estimate

Depending on the degree of detail and accuracy of the national mortality data, six methods have been utilised in the following order of priority: 1. Rates projected to 2012 (69 countries); 2. Most recent rates applied to 2012 population (26 countries); 3. Estimations as the weighted average of regional rates (one country); 4. Estimations from national incidence by modeling, using country-specific survival (two countries); 5. Estimations from national incidence using modeled survival (83 countries); and 6. The rates of neighbouring countries or registries in the same area (three countries) [17-19].

Human development index

The HDI is a composite measure of indicators along with three dimensions: life expectancy, educational attainment, and command over the resources needed for a decent living. All groups and regions had notable improvement in all HDI components, with faster progress in low and medium HDI countries. On this basis, the world is becoming less unequal. Nevertheless, national averages hide large variations in human experience. Wide disparities remain within countries, both in the North and the South, and income inequality within and between many countries has been rising [16].

Statistical analysis

In this study, we used the correlation bivariate method for assessment of the correlation between age ASR and HDI, and its details including life expectancy at birth, mean years of schooling, and gross national income (GNI) per capita. Statistical significance was assumed if P < 0.05. All reported P-values are two-sided. Statistical analyses were performed using SPSS (Version 15.0, SPSS Inc).

Results

In general, Asian countries recorded 110,526 cases of ovarian cancer in 2012. Among these countries, the five countries with the highest number of cases were China (34,575 cases), India (26,834 cases), Indonesia (10,238 cases), Japan (8921 cases), and Pakistan (3703 cases). The five countries included 84,271 cases (24/76%) of patients in Asia. In Asian countries, five countries had the highest standardised incidence of ovarian cancer, as follows: Singapore with 9.9 per 100,000, Kazakhstan with 7.9 per 100,000, Beruni with 8.8 per 100,000, Armenia with 5.8 per 100,000, and Japan with 4.8 per 100,000, respectively. The five countries with the lowest standardised rates of ovarian cancer were Tajikistan with 2 per 100,000, Uzbekistan with 2.1 per 100,000, Azerbaijan with 2.1 per 100,000, Turkmenistan with 2.6 per 100,000, and Vietnam with 2.6 per 100,000 (Table and Figure 1).
Figure 1.

standardised incidence and mortality rates of ovarian cancer in Asia in 2012.

The number of 65,668 deaths because of ovarian cancer occurred in Asian countries in 2012. The greatest number of deaths were in India (19,549), China (14,676), Indonesia (7075), Japan (4986), and Pakistan (2726). The total number of deaths in the five countries was 49,012 (63/74%). In Asian countries, the five countries with the highest standardised death rate of ovarian cancer were as follows: Indonesia 1.6 per 100,000, Brunei with 6 per 100,000, Kazakhstan with 6 per 100,000, Armenia with 5.1 per 100,000, and Israel with 5.1 per 100,000. The five countries with the lowest standardised mortality rate of ovarian cancer included Uzbekistan with 7.1 per 100,000, China with 1.7 per 100,000, Azerbaijan with 1.7 per 100,000, Tajikistanwith 1.8 per 100,000, and Vietnam with 1.9 per 100,000 (Table and Figure 1).
Table 1.

Number, crude and standardised incidence rates, and mortality from ovarian cancer in Asian countries in 2012 (sorted by age-standardised rate from the highest to lowest).

Ovary - Estimated incidence, all agesOvary - Estimated mortality, all ages
POPULATIONNumbersCrude RateASR (W)POPULATIONNumbersCrude RateASR (W)
Singapore37114.29.9Indonesia70755.86.1
Kazakhstan93911.09.7Brunei94.46.0
Brunei167.88.8Kazakhstan6087.16.0
Armenia19311.68.5Armenia1307.85.1
Japan892113.78.4Israel2967.65.1
Indonesia10,2388.38.4United Arab Emirates421.75.0
Malaysia10987.67.8Kyrgyzstan1134.15.0
Lebanon1838.37.5Malaysia6454.54.9
Israel3809.87.3Maldives53.14.8
Maldives95.67.1State of Palestine542.64.7
Korea, Democratic Republic of10898.76.8Nepal5283.44.7
Korea, Republic of23499.66.8Lebanon1165.34.7
United Arab Emirates722.96.4Pakistan27263.14.5
Kyrgyzstan1585.76.3Myanmar10404.24.3
Turkey24006.46.3Timor-Leste122.14.3
Thailand26897.65.9Turkey15884.34.2
Philippines24255.05.9Lao PDR942.94.2
Sri Lanka7366.85.8Singapore1666.44.0
Nepal7024.55.8Philippines14423.03.9
State of Palestine783.75.7Jordan712.33.8
Pakistan37034.25.6Bhutan102.83.8
Myanmar13965.65.5Bangladesh21662.93.7
Jordan1113.55.4Sri Lanka4874.53.6
Lao PDR1294.05.2India195493.23.6
Bhutan154.35.2Syrian Arab Republic2622.53.6
Timor-Leste162.75.1Cambodia2193.03.6
India26,8344.44.9Afghanistan2661.63.5
Syrian Arab Republic3853.74.8Iraq3472.13.5
Iran, Islamic Republic of16374.44.8Japan49867.73.4
Kuwait312.74.7Qatar81.73.4
Qatar143.04.6Iran, Islamic Republic of10762.93.4
Cambodia3004.14.5Yemen2021.63.4
Bahrain152.94.4Kuwait181.53.3
Bangladesh29123.94.4Korea, Democratic Republic of5514.43.2
Iraq4882.94.3Mongolia362.53.2
China345755.34.1Thailand14314.03.1
Yemen2752.23.8Oman171.42.7
Afghanistan3462.13.8Korea, Republic of10544.32.5
Georgia1285.63.7Saudi Arabia1901.52.5
Mongolia463.23.7Bahrain91.82.4
Saudi Arabia3072.43.4Georgia823.62.1
Oman252.13.3Turkmenistan471.82.1
Viet Nam12542.82.6Viet Nam8872.01.9
Turkmenistan652.52.6Tajikistan431.21.8
Azerbaijan1413.02.5Azerbaijan932.01.7
Uzbekistan2751.92.1China146762.21.7
Tajikistan571.62.0Uzbekistan1961.41.7
Table 2 shows values of the HDI and its components for each of the Asian countries. The Asian countries in terms of HDI are classified as follows: the three countries in the very high category, four countries in the high category, thirty-five countries in the middle category, three countries in the low category, and one country in the unknown category.
Table 2.

Human Development Index in Asian countries in 2012.

HDIPOPULATIONHuman Development Index (HDI)Life expectancy at birthMean Year of schoolingGross national income (GNI) per capita
Very highJapan0.91283.611.632545
Korea, Republic of0.90980.711.628,231
Israel0.981.911.926,224
HighSingapore0.89581.210.152,613
Brunei0.85578.18.645,690
Qatar0.83478.57.387478
United Arab Emirates0.81876.78.942,716
MediumBahrain0.79675.29.419,154
Kuwait0.7974.76.152,793
Saudi Arabia0.78274.17.822,616
Malaysia0.76974.59.513,676
Kazakhstan0.75467.410.410,451
Georgia0.74573.912.15005
Lebanon0.74572.87.912,364
Iran, Islamic Republic of0.74273.27.810,695
Azerbaijan0.73470.911.28153
Oman0.73173.25.524,092
Armenia0.72974.410.85540
Turkey0.72274.26.513,710
Sri Lanka0.71575.19.35170
Jordan0.773.58.65272
China0.69973.77.57945
Turkmenistan0.69865.29.97782
Thailand0.6974.36.67722
Maldives0.68877.15.87478
Mongolia0.67568.88.34245
State of Palestine0.677383359
Philippines0.654698.93752
Uzbekistan0.65468.6103201
Syrian Arab Republic0.648765.74674
Indonesia0.62969.85.84154
Kyrgyzstan0.622689.32009
Tajikistan0.62267.89.82119
Viet Nam0.61775.45.52970
Iraq0.5969.65.63557
Timor-Leste0.57662.94.45446
India0.55465.84.43285
Cambodia0.54363.65.82095
Lao PDR0.54367.84.62435
Bhutan0.53867.62.35246
Bangladesh0.51569.24.81785
Pakistan0.51565.74.92566
LowMyanmar0.49865.73.91 817
Nepal0.46369.13.21137
Yemen0.45865.95.3928
Afghanistan0.37449.13.11000
UnknownKorea, Democratic Republic of

Standardised incidence rate and HDI

The standardised incidence rate for ovarian cancer had a positive correlation with the HDI, which was statistically significant (p = 0.006). There was a positive correlation between the components of the HDI and standardised incidence rate, so that a positive correlation was seen between the standardised incidence rate and life expectancy at birth (p = .006), the standardised incidence rate and the average years of schooling (0.143), and the standardised incidence rate and the level of income per person of population (p = 0.063) (Figure 2).
Figure 2.

Correlation between HDI and standardised incidence rates of ovarian cancer in Asia in 2012.

The standardised mortality rate and HDI

The standardised mortality rate for ovarian cancer had a negative correlation with the Human Development Index and this association was not statistically significant (p = 0.975). Between the components of the HDI and standardised mortality rate, statistically significant correlation was not observed. So that a positive correlation between the standardised mortality and life expectancy at birth (p = 0.861), a negative correlation between the standardised mortality and mean years of schooling (0.373), and a positive correlation between the standardised mortality and the level of income for each person (p = 0.664) (Figure 3).
Figure 3.

Correlation between HDI and standardised mortality rates for ovarian cancer in Asia in 2012.

Discussion

According to the findings of this study among Asian countries, Singapore, Kazakhstan, and Brunei had the highest standardised incidence rate of ovarian cancer. Studies also showed that Singapore has a high HDI, and the other two countries fell in the middle of the scale. Among these countries, the five countries with the highest rate of ovarian cancer included 84% of cancer cases related to Asian countries. Among these countries, Japan had a very high HDI and four other countries were in the middle of the scale. For standardised incidence rate, Singapore had the highest standardised incidence, and Tajikistan had the lowest. Our data in terms of the relationship between HDI and the standardised incidence rate showed that countries with HDI had a high-standardised incidence rate, and this finding was statistically significant. The standardised mortality rate of ovarian cancer showed that five countries, including India, China, Indonesia, Japan, and Pakistan, had the highest rate of mortality. Overall, the countries included 63.74% of all deaths from ovarian cancer. There was no significant correlation between the HDI and standardised mortality rate. In the absence of screening for ovarian cancer, diagnosis of this disease in the advanced stages leads to this cancer being considered as a fatal disease [19]. Most of the patients are diagnosed in stage 3 (71%) or stage 4 (31%). In other words, identifying this disease is hard, and the survival rate of the disease is low [20]. In addition, it has higher mortality among gynaecological cancers [20]. We also found that in the past, most of the world’s population was made up of children and teenagers, but with ageing (increased longevity) and a decrease in the birth rate, the declining population in the future will be remarkable. Because of increasing life expectancy and decreasing birth rate, the world has become ageing, and problems such as non-communicable diseases, especially cancer in the coming years are increasing. Most of the Asian countries are young, and the pattern of western lifestyle in these countries is progressive. Therefore, this problem will have a particular impact on developing countries. According to the World Health Organisation in 2012, the increasing rate of older populations may lead to an increase in new cancer cases up to 19.3 million in 2025. Most new cases (56.8%) and mortality (64.9%) will occur in developing countries [17]. It is estimated that cancer causes 12.6% of total deaths. It is the second cause of death after heart disease. It is expected that cancer deaths will exceed those because of heart disease [21]. Although an increased incidence was seen in most countries, the difference between developed and developing countries was significant. Although developed countries have the highest incidence rate of cancer, the mortality rate is higher in developing countries. A lack of resources in developing countries leads to late diagnosis of the disease which causes high mortality from cancer in these countries. For example, the incidence of breast cancer in Western Europe was 90 new cases per 100,000 people, while the annual incidence in eastern Africa was 30 per 100,000, and mortality from the disease in these two regions nearly equals 15 per 100,000(21). The incidence of cancer in the different geographic regions can partly be attributed to differences in risk factors related to lifestyle [22]. Several factors affect the occurrence of cancer, including tobacco, alcohol, work-related factors, pollution, water pollution, food and nutrition, obesity, physical activity, infectious agents, and UV radiation [23]. Related risk factors in developed countries include smoking, the pattern of nutritional, and reproductive behaviours, and in developing countries infectious agents, but disease patterns are changing [22]. One of the important factors in reducing the incidence and mortality of cancer can be HDI. The scale evaluates the long-term progress in three areas of human development. It is a composite index of three basic dimensions of human development, including life expectancy at birth, educational attainment (based on a combination of adult literacy rate and primary to tertiary education enrolment rates), and income (based on GDP per head, adjusted for purchasing-power parity in US$) (United Nations Development Programme: Human Development Index [HDI] [24]. Because of the lack of screening for ovarian cancer, its identification occurs at advanced stages, improving standard criteria in HDI, and awareness about lifestyle modification can partly prevent the incidence and mortality of this deadly disease.

Limitations

This was an ecological study. Result of this type of study should be interpreted at the population level, and ecological fallacy will occur if results are inferred and concluded at the individual level. Some other factors such as the number of reproductive and contraceptive factors that suppress ovulation, including gravidity, breast feeding, and oral contraception, reduce the risk of ovarian cancer, and gynaecologic surgeries including hysterectomy and tubal ligation were protective. Some of the environmental factors and medical conditions that increased risk of disease included talc use, endometriosis, ovarian cysts, and hyperthyroidism. However, in this study we do not have access to enough information on these factors to consider their role in the incidence and mortality of ovarian cancer in Asian countries. Therefore, it is suggested that in addition to ecological studies, in each of these countries, studies in the form of case-control or cohort studies should be done to determine the role of factors related to the incidence and mortality from this disease on an individual level.

Conclusions

Based on the findings of this study, ovarian cancer as a fatal disease in countries with low HDI had an increasing trend. The increasing number of elderly people in these countries, the changes in the way of life in these countries, as well as lack of facilities for screening in turn leading to delayed diagnosis, will all contribute towards these countries having to face rising mortality from this disease. Therefore, it seems that health policy makers should make serious decisions in this area to deal with the increase in the incidence and mortality of ovarian cancer. Asian countries are mostly developing countries, and the Western lifestyle in these countries causes a rapid increase in the burden of non-communicable diseases. Preventive programmes should be the top priority in these countries. In general, it can be concluded that by improving the socioeconomic situation, we find the incidence and mortality from infectious diseases and cancers related to infection are reduced, but cancers which are more associated with lifestyle factors are in rise.
  20 in total

1.  Comparison of crude and age-specific incidence rates of breast, ovary, endometrium and cervix cancers in Iran, 2005.

Authors:  Maliheh Arab; Giti Noghabaei; Seyyedeh Neda Kazemi
Journal:  Asian Pac J Cancer Prev       Date:  2014

2.  Awareness of ovarian cancer risk factors among women in Malaysia: a preliminary study.

Authors:  Soon Lean Keng; Syakirah Bainun Abdul Wahab; Lim Bee Chiu; Azlina Yusuf
Journal:  Asian Pac J Cancer Prev       Date:  2015

3.  Changing Trends of Types of Skin Cancer in Iran.

Authors:  Saeid Razi; Hosein Rafiemanesh; Mahshid Ghoncheh; Yousef Khani; Hamid Salehiniya
Journal:  Asian Pac J Cancer Prev       Date:  2015

4.  Global cancer transitions according to the Human Development Index (2008-2030): a population-based study.

Authors:  Freddie Bray; Ahmedin Jemal; Nathan Grey; Jacques Ferlay; David Forman
Journal:  Lancet Oncol       Date:  2012-06-01       Impact factor: 41.316

5.  Priority actions for the non-communicable disease crisis.

Authors:  Robert Beaglehole; Ruth Bonita; Richard Horton; Cary Adams; George Alleyne; Perviz Asaria; Vanessa Baugh; Henk Bekedam; Nils Billo; Sally Casswell; Michele Cecchini; Ruth Colagiuri; Stephen Colagiuri; Tea Collins; Shah Ebrahim; Michael Engelgau; Gauden Galea; Thomas Gaziano; Robert Geneau; Andy Haines; James Hospedales; Prabhat Jha; Ann Keeling; Stephen Leeder; Paul Lincoln; Martin McKee; Judith Mackay; Roger Magnusson; Rob Moodie; Modi Mwatsama; Sania Nishtar; Bo Norrving; David Patterson; Peter Piot; Johanna Ralston; Manju Rani; K Srinath Reddy; Franco Sassi; Nick Sheron; David Stuckler; Il Suh; Julie Torode; Cherian Varghese; Judith Watt
Journal:  Lancet       Date:  2011-04-05       Impact factor: 79.321

6.  Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls.

Authors:  V Beral; R Doll; C Hermon; R Peto; G Reeves
Journal:  Lancet       Date:  2008-01-26       Impact factor: 79.321

Review 7.  Review of epidemiological evidence for reproductive and hormonal factors in relation to the risk of epithelial ovarian malignancies.

Authors:  Tomas Riman; Staffan Nilsson; Ingemar R Persson
Journal:  Acta Obstet Gynecol Scand       Date:  2004-09       Impact factor: 3.636

8.  Correlation of cancer incidence with diet, smoking and socio- economic position across 22 districts of Tehran in 2008.

Authors:  Marzieh Rohani-Rasaf; Morteza Abdollahi; Shima Jazayeri; Naser Kalantari; Mohsen Asadi-Lari
Journal:  Asian Pac J Cancer Prev       Date:  2013

Review 9.  Epidemiology and risk factors in pancreatic cancer.

Authors:  J D Ahlgren
Journal:  Semin Oncol       Date:  1996-04       Impact factor: 4.929

10.  Epidemiology, Incidence and Mortality of Bladder Cancer and their Relationship with the Development Index in the World.

Authors:  Neda Mahdavifar; Mahshid Ghoncheh; Reza Pakzad; Zohre Momenimovahed; Hamid Salehiniya
Journal:  Asian Pac J Cancer Prev       Date:  2016
View more
  18 in total

1.  Enhancing delivery of small molecule and cell-based therapies for ovarian cancer using advanced delivery strategies.

Authors:  Joanne O'Dwyer; Roisin E O'Cearbhaill; Robert Wylie; Saoirse O'Mahony; Michael O'Dwyer; Garry P Duffy; Eimear B Dolan
Journal:  Adv Ther (Weinh)       Date:  2020-08-16

2.  Long non-coding RNA LINC00504 regulates the Warburg effect in ovarian cancer through inhibition of miR-1244.

Authors:  Ya Liu; Xiaocui He; Yuli Chen; Dan Cao
Journal:  Mol Cell Biochem       Date:  2019-11-05       Impact factor: 3.396

3.  Prevalence and its associated psychological variables of symptoms of depression and anxiety among ovarian cancer patients in China: a cross-sectional study.

Authors:  Chun Li Liu; Li Liu; Yi Zhang; Xiao Ze Dai; Hui Wu
Journal:  Health Qual Life Outcomes       Date:  2017-08-17       Impact factor: 3.186

4.  Incidence and mortality of kidney cancer and its relationship with HDI (Human Development Index) in the world in 2012.

Authors:  Maryam Mohammadian; Reza Pakzad; Farhad Towhidi; Behnam Reza Makhsosi; Abbas Ahmadi; Hamid Salehiniya
Journal:  Clujul Med       Date:  2017-07-15

5.  TNFAIP8 promotes cell growth by regulating the Hippo pathway in epithelial ovarian cancer.

Authors:  Yao Xie; Fei Zhou; Xia Zhao
Journal:  Exp Ther Med       Date:  2018-10-02       Impact factor: 2.447

6.  Investigating the Effect of Mindfulness-Based Training on Psychological Status and Quality of Life in Patients with Breast Cancer

Authors:  Somye Pouy; Fatemeh Attari Peikani; Hassan Nourmohammadi; Parisa Sanei; Asma Tarjoman; Milad Borji
Journal:  Asian Pac J Cancer Prev       Date:  2018-07-27

7.  Correlation between municipal human development index and stroke mortality: a study of Brazilian capitals.

Authors:  Diego Monteiro de Melo Lucena; Francisco Winter Dos Santos Figueiredo; Luiz Vinicius de Alcantara Sousa; Laércio da Silva Paiva; Tábata Cristina do Carmo Almeida; Sidnei José Galego; João Antônio Correa; Erika da Silva Maciel; Fernando Adami
Journal:  BMC Res Notes       Date:  2018-08-01

8.  PLAG1 silencing promotes cell chemosensitivity in ovarian cancer via the IGF2 signaling pathway.

Authors:  Wei Huang; Bi-Rong Li; Hao Feng
Journal:  Int J Mol Med       Date:  2020-01-08       Impact factor: 4.101

9.  Temporal Trends of Common Female Malignances on Breast, Cervical, and Ovarian Cancer Mortality in Japan, Republic of Korea, and Singapore: Application of the Age-Period-Cohort Model.

Authors:  Jinyao Wang; Haizhen Lv; Zhilin Xue; Lu Wang; Zhiqiang Bai
Journal:  Biomed Res Int       Date:  2018-03-21       Impact factor: 3.411

10.  Novel biomolecule lycopene-reduced graphene oxide-silver nanoparticle enhances apoptotic potential of trichostatin A in human ovarian cancer cells (SKOV3).

Authors:  Xi-Feng Zhang; Feng-Hua Huang; Guo-Liang Zhang; Ding-Ping Bai; De Felici Massimo; Yi-Fan Huang; Sangiliyandi Gurunathan
Journal:  Int J Nanomedicine       Date:  2017-10-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.